Jennifer S. Michaelson, Chief Scientific Officer at Cullinan Oncology, and Patrick A. Baeuerle, scientific advisor to Cullinan Oncology and honorary professor in immunology at Ludwig Maximilians University Munich, discuss the use of CD19-specific T cell-engaging antibody therapies (TCEs) as therapeutics for autoimmune diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001598 | PMC |
| http://dx.doi.org/10.1084/jem.20240499 | DOI Listing |
Publication Analysis
Top Keywords
cullinan oncology
8
cd19-directed cell-engaging
4
cell-engaging antibodies
4
antibodies treatment
4
treatment autoimmune
4
autoimmune disease
4
disease jennifer
4
jennifer michaelson
4
michaelson chief
4
chief scientific
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!